KPV is the C-terminal tripeptide of alpha-MSH with potent anti-inflammatory activity specifically in the gut. It reduces intestinal inflammation by blocking NF-κB signaling in gut epithelial cells and macrophages, and works best as an oral compound for direct mucosal contact.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
KPV (Lysine-Proline-Valine) is a tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). It retains α-MSH's potent anti-inflammatory properties in a smaller, more stable, and orally bioavailable format. While full α-MSH activates melanocortin receptors broadly, KPV's anti-inflammatory activity in the gut appears to be partially receptor-independent, working through direct modulation of intracellular inflammatory pathways in intestinal epithelial cells. Its combination of oral stability, gut-specific activity, and clean safety profile makes it a primary research compound for inflammatory bowel conditions.
Mechanism of Action
KPV reduces intestinal inflammation by inhibiting NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) — the master transcription factor that drives the production of inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8. It enters intestinal epithelial cells and macrophages where it directly suppresses IκBα degradation, preventing NF-κB nuclear translocation and cytokine transcription. KPV also activates melanocortin receptors (MC1R and MC3R) in gut-associated immune cells, producing anti-inflammatory signaling through the cAMP-PKA pathway. This dual mechanism — NF-κB inhibition plus melanocortin receptor activation — gives KPV a broader anti-inflammatory effect than a simple receptor agonist. It does not suppress systemic immune function.
Key Research
KPV's anti-inflammatory activity was characterized through a series of studies on α-MSH fragments. Cell culture studies established NF-κB inhibition in human intestinal epithelial cells and macrophages at nanomolar concentrations. Animal models of colitis demonstrated KPV reduced inflammatory markers, mucosal damage, and disease activity scores comparably to standard anti-inflammatory agents. Studies confirmed KPV is absorbed across intestinal epithelium via PepT1 transporters — a mechanism that also makes it orally bioavailable. Combined studies with BPC-157 showed additive effects on mucosal healing. Research from the University of Georgia and other groups validated its efficacy in DSS-induced colitis models. No human clinical trials have been conducted.
KPV is used primarily orally for gut applications. Dissolve in water and drink on an empty stomach for maximum mucosal contact, 2–3 times daily. Standard oral dose is 250–500 mcg per dose. For systemic anti-inflammatory effects or non-gut applications, subcutaneous injection at similar doses can be used. KPV can be safely combined in the same dose with BPC-157 oral solution. Cycle: 10 weeks on / 4 weeks off. Works best alongside a low-inflammatory diet and probiotic support.
Gut Healing Stack: KPV 500 mcg orally + BPC-157 500 mcg orally, both dissolved in water and taken together on an empty stomach, twice daily for 4 weeks; reduce to once daily for weeks 5–10. Add Larazotide Acetate 0.5 mg three times daily with meals for comprehensive barrier repair. Anti-Inflammatory Maintenance: KPV 250 mcg orally once daily ongoing for gut health maintenance alongside a probiotic.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
KPV is extremely well tolerated with no significant adverse events documented in research. Its small size and gut-specific activity means minimal systemic absorption and no known systemic side effects at oral doses. Mild GI discomfort during the first few days of use has been occasionally reported, likely related to changes in gut immune activity rather than direct toxicity. No hormonal, endocrine, or hepatic effects have been documented. It does not affect skin pigmentation at oral gut-health doses (unlike full α-MSH). Suitable for daily use in gut health protocols.
Storage & Handling
Store lyophilized KPV at 2–8°C, protected from light. Stable for up to 12 months. Reconstitute with bacteriostatic water or sterile water. For oral use, dissolve in a small amount of water immediately before consumption. Store reconstituted solution at 2–8°C and use within 14–21 days. KPV is a small, relatively stable tripeptide — it is more robust in solution than larger peptides.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
